SEC Form 4 · accession 0001209191-15-006767
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Robichaud
Officer — Chief Scientific Officer
Period of report
Jan 23, 2015
Accepted (ET)
Jan 27, 2015 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $38.25 | Jan 23, 2015 | A | 51,000 | A | — | Jan 23, 2025 | Common Stock | 51,000 | 51,000 | D |
Explanation of responses
- F1The securities awarded on 1/23/2015 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 3,750 shares of common stock shall vest on the one year anniversary of the Vesting Start Date with 11,250 shares vesting in 36 equal monthly installments thereafter. Options to purchase 36,000 shares of common stock shall vest periodically over the next four years upon the recipient reaching certain milestone requirements.